HC010 in First-line PD-L1 Positive Advanced NSCLC Patients

This trial is testing HC010 as a first-line (initial) treatment for people with advanced non-small cell lung cancer (NSCLC) whose tumors test positive for PD-L1 — a protein that makes cancer less visible to the immune system. HC010 is a new drug designed to work as an immunotherapy. **You may be eligible if...** - You are 18 or older - You have locally advanced or metastatic (stage IIIb–IV) non-small cell lung cancer confirmed by biopsy - Your tumor tests positive for PD-L1 on a pathology test - You have not previously received systemic treatment for advanced or metastatic NSCLC (or your prior adjuvant/neoadjuvant treatment ended more than 6 months ago) **You may NOT be eligible if...** - Your tumor has targetable gene mutations (like EGFR, ALK, or ROS1 — different drugs work better for those) - You have active autoimmune disease or are on immune-suppressing medications - You have serious heart, lung, liver, or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.